Business Context and Reporting Period
SciSparc Ltd., a foreign private issuer based in Tel Aviv, Israel, filed Form 6-K on November 20, 2025. The report covers the month of November 2025 and primarily serves to disseminate a press release regarding a strategic collaboration.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative performance data.
Material Changes
No material financial changes versus prior periods are reported in this document. The significant development is the announcement of an Israeli patent application filed by Neurothera Labs in collaboration with Clearmind Medicine for a novel non-hallucinogenic neuroplastogen treatment for depression.
Guidance, Outlook, and Risks
The filing incorporates a press release detailing the patent application but does not provide specific financial guidance, management commentary on future earnings, or a detailed risk assessment. The document notes that the report is incorporated by reference into various registration statements on Form F-3 and Form S-8.
Investor Verification Checklist
- Verify the status and scope of the Israeli patent application filed by Neurothera Labs and Clearmind Medicine.
- Confirm the nature of the collaboration agreement between SciSparc, Neurothera Labs, and Clearmind Medicine.
- Review the referenced registration statements (Form F-3 and Form S-8) for updated capitalization or offering details.
- Check for subsequent filings that may provide financial context or updates on the patent application.